Loading
Aleniglipron / Obesity, Overweight, Or Chronic Weight Management / Aleniglipron or Placebo · Phase 2 Trial
ClinicalTrials.gov · August 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2b dose-range finding trial of aleniglipron in adults with overweight or obesity and weight-related comorbidities. The study has completed recruitment of 230 participants but results are not yet posted in this registry record. No efficacy or safety outcomes can be assessed from this registration alone.
Phase 2, Interventional, Randomized, Parallel, Triple masking, Treatment purpose. Obesity, Overweight, or Chronic Weight Management; age from 18 Years; to 79 Years. Intervention: Cohort 1; Cohort 2; Cohort 3. Compared with: Cohort 1 OLE — Active Comparator; Cohort 2 OLE — Active Comparator; Cohort 3 OLE — Active Comparator; Cohort 4 OLE — Active Comparator. n = 230. 39 sites: United States.
This is a Phase 2b dose-range finding trial of aleniglipron in adults with overweight or obesity and weight-related comorbidities. The study has completed recruitment of 230 participants but results are not yet posted in this registry record. No efficacy or safety outcomes can be assessed from this registration alone.
Results not posted in this registry record; efficacy and safety outcomes cannot be assessed
The source did not state who this applies to in practice.
Phase 2b dose-range finding trial with completed recruitment but no results posted; registry record only describes planned methods and endpoints, not outcomes.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06693843). This is a study registration, not published results. Lead sponsor: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Recruitment status: COMPLETED. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 230 participants (ACTUAL). Conditions: Obesity, Overweight, or Chronic Weight Management. Interventions: DRUG: Aleniglipron or Placebo; DRUG: Aleniglipron or Placebo; DRUG: Aleniglipron or Placebo; DRUG: Aleniglipron; DRUG: Aleniglipron; DRUG: Aleniglipron; DRUG: Aleniglipron. Primary outcome measures: Percent change in body weight from Baseline to Week 36 , Baseline and week 36; TEAEs and SAEs , Baseline and week 72; AESI , Baseline and week 72; Evaluate the safety and tolerability of participants with abnormal laboratory values, including hematology, serum chemistry, and coagulation , Baseline and week 72; Evaluate long-term safety and tolerability of aleniglipron as measured through electrocardiograms (including, but not limited to, the measurements of ventricular HR, PR interval, QRS duration, QT interval, and QTcF) , Baseline and week 72; Evaluate the safety and tolerability of participants with abnormal vital signs, including blood pressure, heart rate, and temperature , Baseline and week 72. Brief summary: This study is a randomized, double-blind, placebo-controlled, dose-range finding study of the efficacy, safety, tolerability, PK, and PD of multiple doses of aleniglipron in participants living with overweight or obesity with at least one weight-related comorbidity. Participants will be randomized to aleniglipron or placebo in a ratio of 3:1 within each Cohort receiving multiple-ascending, QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 36 weeks of treatment. At the end of the study (after completing 36 weeks of treatment), participants will be offered to continue with an open-label extension (OLE) where they will receive aleniglipron for an additional 36 weeks.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.